AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH
Plain-language summary
This trial is testing chidamide (HDAC inhibitor) combined with azacitidine and other agents for patients with angioimmunoblastic T-cell lymphoma (AITL) or other nodal T-follicular helper (TFH) lymphomas who have been newly diagnosed and have not yet received treatment. This is a Phase 3 trial, which means the treatment is being compared to the current standard of care to determine if it works better. Patients are randomly assigned to different treatment groups. This trial does not currently have sites in the United States.
Who can join (key eligibility)
- Age 18 Years to 70 Years years
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Azacitidine (DRUG): Azacitidine (75mg/ m2) will be administered at day 1-5 by subcutaneous injection of each 21-day cycle. | Chidamide (DRUG): Chidamide (20 mg) will be taken orally twice a week for two weeks of each 21-day cycle. | Cyclophosphamide (DRUG): Cyclophosphamide (750 mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle. | Epirubicin (DRUG): Epirubicin (70mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle. | Vincristine (DRUG): Vincristine (1.4mg/ m2，Max dose 2mg) will be administered by an intravenous injection on day 1of each 21-day cycle. | Prednisone (DRUG): Prednisone (100 mg) will be taken orally from day 1-5 of each 21-day cycle.
Azacitidine, Chidamide, Cyclophosphamide, Epirubicin, Vincristine, Prednisone
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details